An Introduction to Haematological Malignancies
In recent years, advances in our understanding of the pathological mechanisms underlying haematological malignancies have led to improved outcomes. Several novel drug classes are now emerging, including chimeric antigen receptor (CAR) T-cell therapy, molecular targeted therapies, bispecific T-cell engaging antibodies, CD47 blockade therapy and antibody-drug conjugates. Many challenges remain, however, including how best to combine agents and determining where new therapies fit into the treatment paradigm.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.”
Our supporting partners do not constitute an endorsement of the content on this page.
Haematological Malignancies Content
Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinic
Two haematologic oncologists discuss optimizing the use of JAK inhibitors for patients with myelofibrosis.
- Discuss considerations for selecting an appropriate JAK inhibitor in the first-line treatment of myelofibrosis
- Plan strategies for managing side effects associated with JAK inhibition in patients with myelofibrosis
- Evaluate management approaches following lack of treatment success with first-line JAK inhibitor treatment in patients with myelofibrosis
Mark Levis, EHA 2023: MORPHO trial of gilteritinib as post-transplant maintenance for FLT3-ITD acute myeloid leukaemia
BMT-CTN1506 (“MORPHO”) was an international phase III trial investigating the use of post-haematopoietic cell transplantation maintenance with the FLT3 inhibitor, gilteritinib, in patients with FLT3-ITD acute myeloid leukaemia. The aims and findings of the trial, as well as questions that remain to be answered, are discussed in this touchHAEMATOLOGY interview with Dr Mark Levis (Sidney […]
Jorge Cortes, EHA 2023: The use of quizarpenib in patients with acute myeloid leukaemia
We caught up with Prof Jorge Cortes (Georgia Cancer Center, Augusta University, GA, USA) to discuss his highlights from the recent EHA 2023 Congress, including two clinical trials that investigated the use of quizarpenib in patients with acute myeloid leukaemia. Abstracts discussed: Abstract S130: ‘Preliminary Results of QUIWI: A Double Blinded, Randomized Clinical Trial Comparing […]
John Mascarenhas, EHA 2023: Phase II MANIFEST trial: Pelabresib combined with ruxolitinib for patients with myelofibrosis
The phase II MANIFEST trial (NCT02158858) investigated the use of pelabresib combined with ruxolitinib for patients with myelofibrosis who are JAK inhibitor treatment-naïve. We caught up with Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, NY, USA), one of our valued Editorial Board members, to discuss the latest durability of response and safety results […]
John Mascarenhas, EHA 2023: Overview and limitations of current therapeutic options for myelofibrosis
Myelofibrosis is a complex haematological malignancy for which the current first-line treatment is Janus kinase inhibitors. touchHAEMATOLOGY caught up with one of our valued Editorial Board members, Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, NY, USA) to discuss the current therapeutic options for myelofibrosis and their limitations. The abstract entitled ‘UPDATED DURABILITY […]
Johan de Munter, EBMT 2023: Highlights from the Nurses Group Keynote Lecture
President of the European Oncology Nursing Society, Johan de Munter, discusses the key take-home messages from his Nurses Group Keynote Lecture at the European Society for Blood and Marrow Transplantation (EBMT) annual meeting, 23-26 April 2023. Questions: Please summarise the key points from your Nurses Group Keynote Lecture presented at the EBMT conference 2023 (00:18) […]
Marina Kremyanskaya, EHA 2023: Findings of the REVIVE study of rusfertide in polycythaemia vera
The REVIVE study (NCT0405704) is a phase II study investigating the effect of rusfertide, a first-in-class hepcidin mimetic, on the control of erythrocytosis in patients with polycythaemia vera. touchHAEMATOLOGY caught up with Dr Marina Kremyanskaya (Icahn School of Medicine at Mount Sinai, NY, USA) to discuss the main findings of the REVIVE study and the […]
Marina Kremyanskaya, EHA 2023: The REVIVE study of rusfertide in polycythaemia vera – aims and methodology
The REVIVE study (NCT0405704) is a phase II study investigating the effect of rusfertide, a first-in-class hepcidin mimetic, on the control of erythrocytosis in patients with polycythaemia vera. The unmet needs in the treatment of polycythaemia vera and the aims, rationale and methodology of the REVIVE study are discussed in this touchHAEMATOLOGY interview with Dr […]
Key considerations for treatment selection and sequencing in patients with RRMM: Lessons from real-life clinical practice
Watch three specialists discuss patient cases and share their insights on optimization of treatment selection and sequencing in relapsed/refractory multiple myeloma (RRMM).
- Interpret factors that must be balanced when choosing therapy for patients with RRMM who have relapsed following 1–3 prior lines of therapy
- Evaluate alternative treatment strategies for patients with RRMM following >3 prior lines of therapy
- Identify optimal sequencing strategies for patients with RRMM in both early- and later-line settings
Journal articles and more to your inbox
Get the latest clinical insights from touchHAEMATOLOGYSign me up!